Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2958478 | 0.83 | NPSR1 (0.43) | MAPTNPSR1KDM4EALDH1A1KMT2A | |
| SCHEMBL5635038 | 0.82 | LMNA (0.48) | MAPTNPSR1GAAKDM4EALDH1A1 | |
| SCHEMBL2951160 | 0.81 | MAPT (0.37) | MAPTNPSR1GAARAB9ANPC1 | |
| SCHEMBL2951297 | 0.79 | ALDH1A1 (0.43) | MAPTNPSR1GAARAB9ANPC1 | |
| SCHEMBL2959879 | 0.79 | ALDH1A1 (0.42) | GAANPC1ALDH1A1KMT2AMEN1 | |
| SCHEMBL5635059 | 0.79 | GAA (0.35) | MAPTGAARAB9ANPC1KDM4E | |
| SCHEMBL4576401 | 0.79 | ALDH1A1 (0.48) | MAPTGAANPC1KDM4EALDH1A1 | |
| SCHEMBL5635225 | 0.78 | MAPT (0.37) | MAPTNPSR1 | |
| SCHEMBL2950804 | 0.77 | MAPT (0.36) | MAPTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL5633873 | 0.77 | GAA (0.59) | MAPTGAAKDM4EALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179830-B2 | Substituted thienoimidazoles useful for disease treatment and prevention | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-02-20 | — | — | US | disclosed |
| US-20050075385-A1 | Substituted thienoimidazoles useful for disease treatment and prevention | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075385-A1 | Substituted thienoimidazoles useful for disease treatment and prevention | TPMT, TYMS, SLC19A2 | MAPT 3943/4885NPSR1 4595/4885GAA 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.